Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Notable results from Genentech/Roche Phase II trial are featured in conference's official press program T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the HER2-targeting trastuzumab (Herceptin(R)) antibody
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference
WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the 18 th Annual NewsMakers in the Biotech Industry conference at 10:30 am ET on October 21,
View HTML
Toggle Summary ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II Testing
Event Triggers $3 Million Payment From Sanofi
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results WALTHAM, Mass., Oct 20, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the
View HTML
Toggle Summary ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Lead product candidates have notable developments, while pipeline continues to expand. Recent progress includes positive trastuzumab emtansine (T-DM1) clinical data, advancement of SAR3419 to Phase II testing, progress with lead wholly owned compounds, and advancement of BAY 94-9343 partner
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 2, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Company management will present at two investor conferences in the coming weeks.
View HTML
Toggle Summary ImmunoGen, Inc. Earns Milestone From Amgen With IND Achievement
Active IND for New TAP Compound Triggers $1 Million Payment to ImmunoGen
View HTML
Toggle Summary ImmunoGen, Inc. Named One of The Boston Globe's 2011 Top Places to Work
WALTHAM, Mass., Nov. 7, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it has been named one of The Boston Globe's 2011   Top Places to Work.
View HTML
Toggle Summary ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP Compound
Second Active IND Triggers Another $1 Million Payment to ImmunoGen
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 22nd Annual Healthcare Conference
WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Oppenheimer 22 nd Annual Healthcare Conference at 3:55 pm ET on December 13, 2011 will be
View HTML